Cart
sales@molnova.com
Home - Products - Angiogenesis - PDGFR - Rinucumab

Rinucumab

CAS No. 1569263-06-4

Rinucumab( —— )

Catalog No. M36761 CAS No. 1569263-06-4

Rinucumab (REGN 2176) is an anti-platelet-derived growth factor (PDGF) IgG4-like monoclonal antibody that acts by binding to the PDGF-β receptor and can be used to study age-related macular degeneration.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 687 In Stock
10MG 937 In Stock
25MG 1416 In Stock
50MG 1832 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Rinucumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Rinucumab (REGN 2176) is an anti-platelet-derived growth factor (PDGF) IgG4-like monoclonal antibody that acts by binding to the PDGF-β receptor and can be used to study age-related macular degeneration.
  • Description
    Rinucumab (REGN 2176), a monoclonal antibody, is a PDGF inhibitor. Rinucumab (REGN 2176) could be used for the study of neovascular age-related macular degeneration.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    PDGFR
  • Recptor
    PDGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1569263-06-4
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Megan Cully, et al. Deal watch: Novartis eyes vision-enhancing therapy for macular degeneration. Nat Rev Drug Discov. 2014 Jul;13(7):487.?
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • Efinaconazole

    Efinaconazole(KP-103) is an Azole Antifungal currently under development as a topical treatment for onychomycosis.

  • Olaratumab

    Olaratumab(IMC-3G3) is a human monoclonal IgG1 antibody against platelet-derived growth factor receptor alpha (PDGFRα), which has antitumor effects and can be used to study advanced soft tissue sarcomas.

  • BMS-5

    BMS-5 is a potent LIMK inhibitor with IC50s of 7 nM and 8 nM for LIMK1 and LIMK2, respectively.

Sign In Join Free